CYP19A1 and endometrial cancer: Aromatase inhibitors are preferred to SERMs for the treatment of early-stage, ER-positive cancer in postmenopausal women because of superior efficacy in both the neoadjuvant and adjuvant settings.48,49 Also, they do not increase the risk of VTE or endometrial cancer, but they are associated with an increased risk of musculoskeletal pathology, cardiovascular disease, and hyperlipidemia.50 Although in vivo evidence suggests that AIs may impair wound healing, this has not been substantiated clinically.51 Presently, it is not recommended to discontinue AI therapy in the perioperative period.